CNBC July 23, 2024
Annika Kim Constantino, Ashley Capoot

Good afternoon! The first round of the Biden administration’s Medicare drug price negotiations is nearly finished, with two major deadlines approaching.

President Joe Biden’s signature Inflation Reduction Act gave Medicare the power to directly hash out drug prices with manufacturers for the first time in the federal program’s nearly six-decade history. That process aims to make expensive medications more affordable for older Americans, but the pharmaceutical industry argues that it is a threat to their revenue, profits and drug innovation.

The government and manufacturers have been in talks since February, when Medicare sent its initial price offer for each of the 10 medications selected almost a year ago. That includes diabetes treatments from Merck, AstraZeneca and Boehringer Ingelheim...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Congress / White House, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech
Podcast: The Scope of Medicare Fraud
Harnessing AI to reduce Medicare errors, improve accuracy, and ease physician burnout
Report: Prices for top Medicare Part D drugs nearly doubled since entering the market
Pharmacy benefit managers steer Medicare patients to use their own pharmacies
Medicare and telehealth: more restrictive rules could hit patients in 2025

Share This Article